Introduction
Cobicistat (trade name: Tybost) been approved in Germany since September 2013 for the treatment of HIV-1 in adults. As of March 2020 it is also an option for the treatment of HIV-1 in teenagers aged 12 and over.
The human immunodeficiency (HIV) multiplies in cells of the and destroys them. Without proper treatment, the immune system of most HIV patients is weakened so much over time that they become seriously ill. This stage is called “AIDS” (acquired immunodeficiency syndrome).
Although the currently available medications can't cure HIV, they can prevent immunodeficiency for many years. But in some people the medication may become ineffective over time, allowing the viruses to multiply more again.
Cobicistat is a booster: It is combined with atazanavir or darunavir in order to enhance their effect.